On Sept. 27, 2021, RELIEF THERAPEUTICS reported its U.S. collaboration partner, NRx Pharmaceuticals, had announced top line data demonstrating improved outcomes at one year in highly comorbid patients with COVID-19 who were treated with ZYESAMIﾙ (RLF-100 ﾙ/aviptadil).

In highly comorbid COVID-19 patients, ZYESAMIﾙ provided a threefold, statistically significant increase in the likelihood of survival at one year, consistent, according to NRx, with the increased odds of 60-day survival seen in the previously reported results from the phase 2b/3 randomized controlled trial of ZYESAMIﾙ (RLF-100 ﾙ/aviptadil).